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Objective: To study the effect of candesartan cilexetil (CC) in the management of blood pres-
sure (BP) in diabetic and non-diabetic hypertensive patients.
Methods: A selection of ﬁve randomized double-blind clinical trials in which patients were 
treated for hypertension with CC was analyzed. All of these were similar in design: i) a 4-week 
placebo run-in period, ii) a 4- to 6-week period (V1) with CC 8 mg once daily (od), after which 
the dosage was doubled if BP was not normalized (BP >140/90 or BP >130/80 mmHg in 
diabetes), and iii) a 4- to 6-week period (V2) with CC 8 or 16 mg od. Efﬁcacy was measured 
at V1 and V2.
Results: 702 patients were screened. The population consisted of 397 males (56.6%) with a 
mean age of 60 ± 11 years, with 153 diabetic (21.8%) and 549 non-diabetic (78.2%) patients. 
At baseline, mean BP values were 160/94/65 mmHg for SPB, DBP, and pulse pressure (PP) 
respectively, with differences between diabetic and non-diabetic patients. SBP, DBP, and 
PP values showed a signiﬁcant reduction at V1 (p < 0.001) and V2 (p < 0.001) compared 
with baseline for all hypertensive patients. Mean changes at V2 in SBP and PP values were 
higher in diabetic than non-diabetic patients (p < 0.001), and to a lesser degree on DBP 
values (p = 0.034).
Conclusions: CC was effective in lowering BP in diabetic and non-diabetic hypertensive 
patients. CC is a promising therapy to manage hypertensive diabetic patients, as demonstrated 
by the signiﬁcant BP reduction.
Keywords: candesartan cilexetil, hypertension, antihypertensive diabetes, blood pressure 
lowering, angiotensin II receptor antagonist 
Short abstract: The effect of candesartan cilexetil (CC) on controlling blood pressure (BP) 
in hypertensive diabetic and non-diabetic patients was analyzed. Five randomized double-blind 
trials were pooled treating hypertension by CC (n = 702), including 153 diabetic (21.8%) and 
549 non-diabetic (78.2%) patients. After treatment with CC (8–16 mg), signiﬁcant reductions 
in SBP, DBP, and pulse pressure (PP) values were observed after 4–6 weeks (p < 0.001) and 
after 8–12 weeks (p < 0.001) compared with baseline for all hypertensive patients. Mean BP 
reductions after 8–12 weeks were higher in diabetic patients than non-diabetic (p < 0.001). CC 
is a promising therapy to treat hypertensive patients, both diabetic and non-diabetic.
Introduction
Essential hypertension is the most prevalent cardiovascular disease in the world, and 
a major public health issue. Its prevalence is increasing in the adult population, and 
is estimated to be 30% in developed countries (Asmar et al 2001; Guidelines Com-
mittee 2003). Arterial hypertension, in which insulin resistance is common, is strongly 
associated with type 2 diabetes. Diabetes mellitus is increasing rapidly worldwide, 
and since many patients with hypertension develop diabetes, this combination of risk 
factors will account for a large proportion of cardiovascular morbidity and mortality 
(HDSG 1993; Stamler et al 1993).Vascular Health and Risk Management 2007:3(1) 166
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International Guidelines for the Management of Hyper-
tension have emphasized that blood pressure (BP)-lowering 
therapy can reduce macrovascular disease for diabetic 
patients which may be more signiﬁcant than blood glucose 
control (Staessen et al 1997). Results from different studies 
(Hansson et al 1998; UKPDS 33 1998; UKPDS 34 1998; 
UKPDS 38 1998) have demonstrated that aggressive lowering 
of diastolic BP (DPB) in diabetic patients was accompanied 
by reductions of macrovascular and microvascular events. 
In addition, the aggressive antihypertensive treatment of 
diabetic patients with systolic hypertension has been favored 
in some studies (SHEP Cooperative Research Group 1991; 
Bakris et al 2000; Chaudhry et al 2004).
Pharmacological agents recommended as initial therapy 
for diabetic patients include diuretics, β-blockers, angiotensin 
converting enzyme (ACE) inhibitors, calcium channel block-
ers, and angiotensin II blocker receptors (ARBs) (Guidelines 
Subcommittee 1999; Chobanian et al 2003). The choice 
of antihypertensive drug regimen in diabetic subjects is 
important for several reasons: they are susceptible to suffer 
metabolic decompensation, and the diabetic state may alter 
the pharmacokinetics of several cardiovascular drugs 
(Preston et al 2001). In this way, captopril was found 
superior to a diuretic/β-blocker antihypertensive treat-
ment in diabetic patients, especially in those with metabolic 
decompensation (Niskanen et al 2001). Consequently, dosage 
requirements established for non-diabetic patients, when 
applied to the patient with diabetes, may potentially result 
in either therapeutic failure or undesirable adverse effects. 
Some epidemiological and clinical studies suggested a 
causal link between the use of thiazide diuretics and the 
subsequent development of type 2 diabetes (Bengtsson 
et al 1984; Padwal and Laupacis 2004), and β-blockers 
are not speciﬁcally indicated in diabetic patients (Scheen 
2004). ACE inhibitors (Trost and Weidman 1987; Pollare 
et al 1989; Berne et al 1991; Oksa et al 1994; Padwal and 
Laupacis 2004; Scheen 2004) and calcium channel antago-
nists (Trost and Weidmann 1987; Padwal and Laupacis 
2004; Scheen 2004) have little or no signiﬁcant effects 
on plasma glucose and insulin levels in patients with and 
without diabetes. 
ARBs have beneﬁcial renal effects in patients with 
diabetes and nephropathy (Brenner et al 2001; Lewis et 
al 2001; Parving et al 2001; Lindholm et al 2002). A re-
cent study demonstrated that a subset of angiotensin receptor 
antagonists (ARAs) induces peroxisome proliferators-acti-
vated receptor (PPARγ), providing a potential mechanism 
for their insulin-sensitizing/antidiabetic effects (Scheen 
2004) and an opportunity for the prevention and treat-
ment of diabetes and cardiovascular disease in high-risk 
populations (Pershadsingh and Kurtz 2004). Among 
the ARBs, candesartan cilexetil (CC) is a potent, highly 
selective, angiotensin II type 1 (AT1) blocker receptor. Due 
to tight binding to and slow dissociation from the receptor, 
CC provides a strong, dose-dependent, and long-lasting anti-
hypertensive effect. CC does not affect glucose homeostasis 
or the serum lipid proﬁle (Trenwalder et al 1998), and is 
effective in reducing BP and microalbuminuria (Mogensen 
et al 2000) in hypertensive patients with type 2 diabetes. 
Five randomized double-blind studies (Denolle et al 2001; 
Imbs and Nisse-Durgeat 2005; Baguet et al 2006; Olivier JP, 
pers comm; Baguet JP, pers comm) demonstrated the 
efﬁcacy of CC (8–16 mg) in controlling hypertensive 
patients. Whether this efﬁcacy is similar in diabetic and 
non-diabetic patients is not yet established. The aim of 
this study was to analyze the effect of CC on BP in these 
two populations by pooling data from ﬁve randomized 
double-blind clinical trials (Denolle et al 2001; Imbs and 
Nisse-Durgeat 2005; Baguet et al 2006; Olivier JP, pers 
comm; Baguet JP, pers comm). 
Materials and methods
Study population
This was a retrospective data meta-analysis of ﬁve random-
ized double-blind studies (Trenkwalder et al 1998; Mogensen 
et al 2000; Imbs and Nisse-Durgeat 2005; Baguet JP, pers 
comm; Olivier JP, pers comm) evaluating the efﬁcacy of 
CC (8–16 mg). These ﬁve studies had a similar design: 
2- to 4-week placebo wash out period, followed by 4- to 
6-week double-blind period where patients received the 
active drug once daily. After this period, if BP was not 
normalized (SBP or DBP ≥140/90 mmHg or ≥130/80 
mmHg in diabetes patients) the treatment could be doubled 
during another 4- to 6-week period. Efﬁcacy was analyzed 
at V1 (after the ﬁrst CC period treatment) and at V2 (after 
the second period treatment). A total of 702 patients treated 
by CC were included in this analysis.
Statistical analysis
All statistical analysis was undertaken using a Number 
Cruncher Statistical System (NCSS 2000, Kaysville, Utah, 
USA). Quantitative variables were expressed as mean ± SD, 
minimum and upper values, and were compared using a 
Student’s t-test; a Wilcoxon test was performed if the data Vascular Health and Risk Management 2007:3(1) 167
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were not normally distributed. Qualitative variables were 
expressed as absolute number and percentage values, and 
were analyzed using a Chi-square test.
Mean pressure values were compared before and after CC 
treatment in each group, and between groups (diabetic and 
non-diabetic patients) using a t-test. Final blood pressure (V1 
and V2) comparison between diabetic and non-diabetic group 
was performed by a covariance analysis with and adjustment 
to the initial BP values and weight. P < 0.05 was considered 
statistically signiﬁcant.
Results
Patients
The patient characteristics are presented in Table 1. This 
analysis included 702 hypertensive patients composed of 
two sub-groups: 153 of diabetic patients (21.8%) and 549 
of non-diabetic patients (78.2%). Patients were principally 
men (57%), with 60 ± 11 years of age. Diabetic patients 
had higher weight values than non-diabetic patients. At 
baseline, systolic and diastolic blood pressure values were 
signiﬁcantly higher in non-diabetic patients compared with 
diabetic (Table 1). 
Antihypertensive effect of candesartan 
cilexetil
Blood pressure reduction in overall population
Changes of SBP, DBP, and pulse pressure (PP) values after 
CC treatment for all patients are shown in Figure 1. Blood 
pressure values showed a signiﬁcant decrease at V1 and V2 
following CC 8–16 mg treatments. In the global population 
signiﬁcant reductions at V1 (p < 0.001) and V2 (p < 0.001) 
were found for SBP, DBP, and PP (Figure 1a). The most 
important change occurred between baseline and V1 (SBP/
DBP/PP: –14/–9/–5 mmHg), but the BP values continued 
to decrease up to V2 (SBP/DBP/PP: –18/–10/–7 mmHg), 
reaching ﬁnal BP values of 141/83/58 mmHg for SBP, DBP, 
and PP respectively (Figure 1a). Mean changes in heart rate 
were not signiﬁcant at V1 (–0.2 bpm) or at V2 (–1.1 bpm), 
reaching a ﬁnal value of 72 bpm.
Blood pressure reduction in diabetic patients
In diabetic patients, signiﬁcant reductions at V1 (p < 0.001) 
and V2 (p < 0.001) were found for SBP, DBP, and PP   
(Figure 1b). The most important change occurred between 
baseline and V1 (SBP/DBP/PP: –14/–9/–5 mmHg), but the 
BP values continued to decrease up to V2 (SBP/DBP/PP: 
–21/–11/–10 mmHg), reaching ﬁnal BP values of 137/82/55 
mmHg for SBP, DBP, and PP respectively (Figure 1b). Mean 
changes in heart rate were not signiﬁcant at V1 (–0.3 bpm) 
or at V2 (–1.3 bpm), reaching a ﬁnal value of 73 bpm.
Blood pressure reduction in non-diabetic patients
In non-diabetic patients, significant reductions at V1 
(p < 0.001) and V2 (p < 0.001) were found for SBP, 
DBP, and PP (Figure 1c), with the most important change 
between baseline and V1 (SBP/DBP/PP: –14/–9/–5 mmHg), 
and a less pronounced decrease up to V2 (SBP/DBP/PP: 
–17/–11/–7 mmHg), reaching ﬁnal BP values of 143/84/59 
mmHg for SBP, DBP, and PP respectively (Figure 1c). Mean 
changes in heart rate were not signiﬁcant at V1 (–0.2 bpm) 
or at V2 (–1 bpm), reaching a ﬁnal value of 72 bpm.
Comparison of antihypertensive effect of CC in 
diabetic and non-diabetic patients
Table 2 compares mean changes of BP and heart rate val-
ues between diabetic and non-diabetic patients. At V1, the 
reductions observed in BP and heart rate values compared 
with baseline were similar for both diabetic and non-dia-
betic patients. At V2, the reductions observed in BP values 
Table 1 Baseline characteristics of patients
  Diabetic  Non-diabetic  Total 
  n = 153  n = 549  n = 702  P values
Age, years  60 ± 9  60 ± 12  60 ± 11  NS
Male, n (%)  88 (57.5)  309 (56.3)  397 (56.6)  NS
Weight, kg  84 ± 17  75 ± 15  77 ± 15  <0.001
Height, cm  165 ± 8  167 ± 9  167 ± 9  NS
Systolic BP, mmHg  158 ± 13  160 ± 13  160 ± 13  0.03
Diastolic BP, mmHg  92 ± 9  95 ± 10  94 ± 10  <0.001
Pulse pressure, mmHg  66 ± 13  65 ± 14  65 ± 14  NS
Heart rate, bpm  75 ± 10  73 ± 10  73 ± 10  NS
Results are given as mean ± SD.Vascular Health and Risk Management 2007:3(1) 168
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Figure 1 Mean changes in systolic blood pressure (SBP), diastolic blood pressure (DBP), and pulse pressure (PP) compared with the baseline at V1 (4–6 weeks) and V2 
(8–12 weeks) in the global population (a), hypertensive diabetic patients (b), and hypertensive non-diabetic patients (c) treated by CC 8–16 mg. Mean values are given, 
standard deviation is shown in parentheses. 
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compared with the baseline were more important in diabetic 
patients for SBP, DBP and PP values (p < 0.001) than in 
non-diabetic patients (Table 2). The mean changes in heart 
rate were not statistically signiﬁcant between diabetic and 
non-diabetic patients.
Discussion
Previous studies have shown that antihypertensive agents 
may exert different effects on glycemic control. In general, 
ACE inhibitors, ARAs, and calcium channel blockers seem 
to have neutral or beneﬁcial effects, whereas β-blockers and 
thiazide diuretics tend to worsen insulin resistance for gly-
cemic control (Bengtsson et al 1984; Padwal and Laupacis 
2004; Scheen 2004). However, studies have shown conﬂict-
ing results, even between agents within the same classes 
(Padwal and Laupacis 2004). Rather than using surrogate 
blood pressure end points, with different antihypertensive 
agents, it may be more clinically relevant to examine the 
effect of the same treatment on controlling hypertensive 
diabetic and non-diabetic patients. Several trials have been 
conducted in diabetic patients comparing two or more drugs 
(Estacio et al 1998; UKPDS 39 1998; HOPE 2000; Lindholm 
et al 2000, 2002; Mogensen et al 2000; Niskanen et al 2001; 
Mancia et al 2003), or an active drug against placebo (SHEP 
Cooperative Research Group 1991; Trenkwalder et al 1998; 
Lithell et al 2003) but only few studies have evaluated blood 
pressure lowering using one drug in the same study compar-
ing the effect in diabetic and non-diabetic patients (Jaichenko 
et al 1998; Preston et al 2001; Gottlieb et al 2003).
The present analysis pooled data of ﬁve randomized 
double-blind clinical trials (Denolle et al 2001; Imbs and 
Nisse-Durgeat 2005; Baguet et al 2006; Olivier JP, pers 
comm; Baguet JP, pers comm) with the objective of analyz-
ing the effect of CC on diabetic and non-diabetic patients. The 
antihypertensive effect of CC 8–16 mg was observed by BP 
reduction achieved by 12 weeks in all patients treated. 
BP values in diabetic hypertensive patients are usually 
higher than in non-diabetic patients despite the use of larger 
number of drugs (Estacio et al 1998; Jaichenko et al 1998; 
UKPDS 39 1998; HOPE 2000; Lindholm et al 2000, 2002; 
Brenner et al 2001; Lewis et al 2001; Niskanen et al 2001; 
Parving et al 2001; Gottlieb et al 2003; Lithell et al 2003; 
Mancia et al 2003). Indeed, treatment is accompanied by 
large BP reductions, but while achieved DBP is almost 
invariably well below 90 mmHg and even 80 mmHg, the 
concomitant SBP remained above 140 mmHg (Brenner 
et al 2001; Lewis et al 2001; Parving et al 2001; Lindolm 
et al 2002). Thus, in hypertensive diabetic patients treated 
with irbesartan 300 mg or amlodipine 10 mg, the ﬁnal 
average SBP/DBP values were 140/77 mmHg and 141/77 
mmHg respectively (Lewis et al 2001). Irbesartan 150 mg 
and irbesartan 300 mg administrated to hypertensive diabetic 
patients with nephropathy gave ﬁnal SBP/DBP values of 
143/83 and 141/83 mmHg, respectively (Parving et al 2001). 
Hypertensive diabetic patients treated by losartan achieved 
mean SBP/DBP ﬁnal values of 140/74 mmHg vs placebo 
(Brenner et al 2001), and of 146/79 mmHg vs atenolol 
(Lindolm et al 2002). 
In a previous study, CC 8–16 mg lowered SBP/DBP 
values to 149/89 mmHg compared with 151/90 with placebo 
(Trenkwalder et al 1998). In the present analysis, a more 
important reduction in mean SBP, DBP, and PP values was 
observed in diabetic (137/82/55 mmHg) compared with non-
diabetic patients (143/84/59 mmHg). 
Table 2 Blood pressure changes in diabetic and non-diabetic hypertensive patients
  Diabetic n = 153    Non-diabetic n = 549 
  Mean ± SD  Mean change ± SD  Mean ± SD  Mean change ± SD  p
V1a           
Systolic BP, mmHg  143 ± 17  –14 ± 14  146 ± 16  –14 ± 15  NS
Diastolic BP, mmHg  84 ± 10  –9 ± 10  86 ± 10  –9 ± 10  NS
Pulse pressure, mmHg  59 ± 12  –5 ± 11  60 ± 13  –10 ± 9  NS
Heart Rate, bpm  74 ± 9  –0.3 ± 7  73 ± 9  –0.2 ± 9  NS
V2b         
Systolic BP, mmHg  137 ± 15  –21 ± 15  143 ± 15  –17 ± 14  <0.001
Diastolic BP, mmHg  82 ± 9  –11 ± 9  84 ± 10  –10 ± 10  0.034
Pulse pressure, mmHg  55 ± 10  –10 ± 13  60 ± 13  –7 ± 13  <0.001
Heart rate, bpm  73 ± 9  –1.3 ± 7  72 ± 9  –1 ± 9  NS
Mean change values were obtained comparing with the baseline. 
aV1: 4- to 6-week period of treatment with CC 8 mg once daily. 
bV2: 8- to 12-week period of treatment with 8–16 mg once daily.Vascular Health and Risk Management 2007:3(1) 170
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In spite of a good response to CC in BP lowering, the 
recommendations to lower SBP in diabetic patients to values 
below 130 mmHg were not totally achieved. The difference 
in the BP response between diabetic and non-diabetic patients 
may partly be explained by a physiological mechanisms dif-
ferently acting in diabetic and non diabetic patients. 
Several randomized clinical trials suggested that the 
inhibition of the renin-angiotensin (RA) system reduces the 
risk of new onset of type 2 diabetes mellitus (T2DM) in pa-
tients with arterial hypertension (Padwal and Laupacis 2004; 
Scheen 2004) or with congestive heart failure (Padwal and 
Laupacis 2004). Considering the pandemic of T2DM, such a 
pharmacological approach deserves further attention among 
the strategies aiming at preventing the disease. This preven-
tive effect of the RA inhibition should involve the intimate 
mechanisms of the complex pathophysiology of T2DM. A 
Japanese study suggested that hypoadiponectinemia is related 
to insulin resistance in essential hypertension (Furuhashi et al 
2003). It also showed that treatment with temocarpil or can-
desartan signiﬁcantly decreases blood pressure and increased 
insulin-mediated glucose disposal and plasma adiponectin 
concentrations (Furuhashi et al 2003). These observations 
require further investigation. 
Another possible mode of action has been hypothesized 
for ARBs. A recent study (Mancia and Grassi 2002) dem-
onstrated that a subset of ARAs induces PPAR-γ activity 
by interaction with the PPAR-γ ligand binding domain. 
ARAs with PPAR-γ activating properties at low (telmis-
artan), medium (irbesartan), and very high concentrations 
(losartan) as well as a non-activating ARA (eposartan) have 
been identiﬁed. The authors concluded that molecules that 
can simultaneously block the ATII receptor and activate 
PPAR-γ have the potential to treat both hemodynamic and 
biochemical features. 
CC has been useful in treating hypertensive patients who 
have experienced side-effects with other antihypertensive 
agents. Its good tolerability has been reported and favorable 
effects on target organ damage, morbidity, and mortality were 
achieved in long-term studies (Lithell et al 2003). The lower 
rate of new-onset diabetes mellitus reported in the CC group 
compared with the control group found in SCOPE is of the 
same magnitude as that observed in the other ARB losartan-
treated group compared with the β-blocker treated group in 
the LIFE study (Lindholm et al 2002). A more favorable 
metabolic proﬁle and a lower risk of developing diabetes 
in hypertensive patients treated with CC 16 mg was also 
described in the ALPINE study (Lindholm et al 2003). 
CC has potential as initial treatment of hypertension and, 
as shown in the present analysis, CC was effective in diabetic 
as well as in non-diabetic patients, and furthermore, with a 
signiﬁcant SBP, DBP, and PP lowering in diabetic patients. 
CC merits further investigation in diabetic patients.
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